Pharma Focus Asia

Merck Invests US$354 million (€300 million) to Open Science Research Centre in Germany


Merck invests US$354 million (€300 million) to open new life science research centre in Germany.


The advanced research centre focuses on conducting research into manufacturing antibodies, mRNA applications, and other biotechnological products. 

Spanning approximately 18,000 square metres, the centre promotes collaboration across departments in a contemporary, open workspace. The carefully engineered facades, alongside the incorporation of green roofs, play a pivotal role in conserving energy and enhancing the microclimate.

It serves as a hub for research into critical technologies including the development of raw materials and processes for manufacturing antibodies, recombinant proteins, and viral vectors. 

Additionally, the centre facilitates research into chemical substance separation, identification, and quantification within samples, as well as research along the mRNA value chain.

By the beginning of 2027, the centre will accommodate around 550 employees.


Name       Merck
Type         New Construction
Budget    US$354 million (€300 million)

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference